NZ269552A - Pharmaceutical composition comprising sparingly water soluble agent in a carrier comprising a triglyceride, non-ionic surfactant and polyglycerol- or sorbitan fatty acid ester - Google Patents

Pharmaceutical composition comprising sparingly water soluble agent in a carrier comprising a triglyceride, non-ionic surfactant and polyglycerol- or sorbitan fatty acid ester

Info

Publication number
NZ269552A
NZ269552A NZ269552A NZ26955294A NZ269552A NZ 269552 A NZ269552 A NZ 269552A NZ 269552 A NZ269552 A NZ 269552A NZ 26955294 A NZ26955294 A NZ 26955294A NZ 269552 A NZ269552 A NZ 269552A
Authority
NZ
New Zealand
Prior art keywords
fatty acid
carrier
acid ester
triglyceride
sorbitan fatty
Prior art date
Application number
NZ269552A
Inventor
Ulrich Posansaki
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6492300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ269552(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NZ269552A publication Critical patent/NZ269552A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pharmaceutical prepn. comprises () a pharmaceutically active agent which is sparingly soluble in water; and (b) a carrier compsn. comprising (i) at least one polyglycerine fatty acid ester and/or at least one sorbitan fatty acid ester, (ii) at least 1 conventional pharmaceutical oil contg. a triglyceride as lipophilic component and (iii) at least 1 nonionic surfactant with a HLB value of at least 10. The active agent is pref. a cyclosporin, rapamycin, tacrolimus, deoxyspergualine, nifedipine, nimodipine, etoposide, ibuprofen or alpha-lipoic acid. The active agent has a solubility, in distilled water, of less than 500mg/1000ml. The active agent concn. is 1-30 wt.%, based on the carrier compsn. The carrier compsn. comprises 10-50 wt.% component (i), 5-40 wt% component (ii) and 10-50 wt % component (iii).
NZ269552A 1993-07-08 1994-07-08 Pharmaceutical composition comprising sparingly water soluble agent in a carrier comprising a triglyceride, non-ionic surfactant and polyglycerol- or sorbitan fatty acid ester NZ269552A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4322826A DE4322826A1 (en) 1993-07-08 1993-07-08 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
NZ269552A true NZ269552A (en) 1996-07-26

Family

ID=6492300

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ269552A NZ269552A (en) 1993-07-08 1994-07-08 Pharmaceutical composition comprising sparingly water soluble agent in a carrier comprising a triglyceride, non-ionic surfactant and polyglycerol- or sorbitan fatty acid ester
NZ269808A NZ269808A (en) 1993-07-08 1994-07-08 Pharmaceutical composition for the solubilisation of a poorly soluble active agent comprising polyglycerol and/or sorbitan fatty acid ester, a triglyceride and a non ionic surfactant

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ269808A NZ269808A (en) 1993-07-08 1994-07-08 Pharmaceutical composition for the solubilisation of a poorly soluble active agent comprising polyglycerol and/or sorbitan fatty acid ester, a triglyceride and a non ionic surfactant

Country Status (24)

Country Link
EP (3) EP1092429B1 (en)
JP (4) JPH08512303A (en)
KR (2) KR100386533B1 (en)
CN (2) CN1313154C (en)
AT (3) ATE201985T1 (en)
AU (2) AU689486B2 (en)
BR (1) BR9407002A (en)
CA (2) CA2164100A1 (en)
CY (2) CY2308B1 (en)
CZ (1) CZ291401B6 (en)
DE (6) DE4322826A1 (en)
DK (3) DK0710103T3 (en)
ES (3) ES2218046T3 (en)
FI (2) FI116197B (en)
GR (1) GR3036571T3 (en)
HU (2) HU228127B1 (en)
NO (2) NO306929B1 (en)
NZ (2) NZ269552A (en)
PL (1) PL179717B1 (en)
PT (2) PT1092429E (en)
RU (1) RU2140291C1 (en)
SI (1) SI1092429T1 (en)
SK (1) SK280615B6 (en)
WO (2) WO1995001786A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6696413B2 (en) * 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
FR2736550B1 (en) 1995-07-14 1998-07-24 Sandoz Sa PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DISPERSION COMPRISING A MACROLIDE AND A VEHICLE
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
GB2317562B (en) * 1995-07-20 1999-08-18 Danbiosyst Uk Lipid vehicle drug delivery composition containing vitamin E
US5597582A (en) * 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
DE19549852B4 (en) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin containing preparations
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
KR20010006070A (en) * 1997-04-11 2001-01-15 후지야마 아키라 Medicinal composition
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
WO2001024780A2 (en) * 1999-10-01 2001-04-12 Natco Pharma Limited Soft gel capsule resistant to gastric juices
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
JP4388743B2 (en) * 2000-11-24 2009-12-24 第一三共ヘルスケア株式会社 Water-soluble oral solution
DE10161077A1 (en) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions for needleless injection
CA2470230C (en) 2001-12-14 2012-01-24 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
KR100533458B1 (en) 2002-07-20 2005-12-07 대화제약 주식회사 Composition for solubilization of paclitaxel and preparation method thereof
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1603560A1 (en) 2003-02-06 2005-12-14 Cipla Ltd. Topical immunotherapy and compositions for use therein
JPWO2004073692A1 (en) * 2003-02-18 2006-06-01 山下　伸二 Hard capsule of poorly water-soluble drug
ES2592504T3 (en) * 2003-07-17 2016-11-30 Banner Life Sciences, LLC Controlled release preparations
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
GB0425255D0 (en) * 2004-11-16 2004-12-15 Novartis Ag Pharmaceutical composition
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
BRPI0614417A2 (en) * 2005-07-28 2011-03-29 Reliant Pharmaceuticals Inc pharmaceutical compositions comprising dihydropyridine calcium channel blockers and omega-3 fatty acids and methods of treatment using them
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
DK2117521T3 (en) 2006-11-03 2012-09-03 Durect Corp TRANSDERMAL ADMINISTRATION SYSTEMS INCLUDING BUPIVACAIN
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
ITMI20070720A1 (en) * 2007-04-06 2008-10-07 Monteresearch Srl ORAL COMPOSITIONS CONTAINING TACROLIMUS IN AMORPHOUS FORM
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CN104997774A (en) * 2009-04-10 2015-10-28 齐海燕 Novel anti-aging agent and method to identify them
CN102647971B (en) 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 For comprising the container of the compositions of meloxicam
WO2011107150A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP5970224B2 (en) 2011-07-11 2016-08-17 株式会社日本自動車部品総合研究所 Spark plug for internal combustion engine
KR20140071913A (en) * 2012-12-04 2014-06-12 삼성정밀화학 주식회사 Food composition and soft capsule including the same
SG11201508358RA (en) * 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
ES2858517T3 (en) * 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Compositions comprising cyclosporin
US20170072058A1 (en) 2014-11-21 2017-03-16 Solipharma Llc Pharmaceutical composition containing tacrolimus and preparation methods thereof
ES2897475T3 (en) 2016-04-20 2022-03-01 Veroscience Llc Composition and method for the treatment of metabolic disorders
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
WO2019079623A1 (en) * 2017-10-18 2019-04-25 Veroscience Llc Improved bromocriptine formulations
PT3765024T (en) * 2018-03-14 2024-02-19 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
CN108853044B (en) * 2018-07-06 2020-11-06 郑州明泽医药科技有限公司 Nifedipine sustained release tablet and preparation method thereof
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
KR102524312B1 (en) * 2020-12-15 2023-04-21 윤관식 Water-soluble emulsion composition comprising ecdysteroid
KR102583074B1 (en) * 2021-01-25 2023-09-25 윤관식 Water-soluble emulsion composition comprising natural polyphenolic compound
WO2022131656A1 (en) * 2020-12-15 2022-06-23 윤관식 Alkaloid-containing, water-soluble emulsified composition
CN113041236B (en) * 2021-03-23 2023-03-10 广州新济药业科技有限公司 Flurbiprofen cataplasm and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1132518A (en) * 1965-02-18 1968-11-06 Richardson Merrell Inc Medicinal composition
IT1090703B (en) * 1976-12-03 1985-06-26 Scherer Ltd R P IMPROVEMENT IN USEFUL COMPOSITIONS SUCH AS DRUG VEHICLES
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
KR0148748B1 (en) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 A multiphase cyclosporin composition
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0525037A (en) * 1991-07-01 1993-02-02 Upjohn Co:The Oral administrative enzyme sensitive enteric coating
DE4322826A1 (en) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmaceutical preparation

Also Published As

Publication number Publication date
FI116197B (en) 2005-10-14
EP0710104B1 (en) 1998-11-04
NZ269808A (en) 1996-07-26
CA2166204A1 (en) 1995-01-19
CA2164100A1 (en) 1995-01-19
JP2011153150A (en) 2011-08-11
DE4494850D2 (en) 1996-08-22
CZ291401B6 (en) 2003-03-12
GR3036571T3 (en) 2001-12-31
BR9407002A (en) 1996-09-03
AU689486B2 (en) 1998-04-02
CY2604B2 (en) 2010-04-28
HUT73427A (en) 1996-07-29
FI116714B (en) 2006-02-15
DE4494851D2 (en) 1996-12-19
EP0710103B1 (en) 2001-06-13
SK280615B6 (en) 2000-05-16
ES2159564T3 (en) 2001-10-16
DK0710103T3 (en) 2001-09-24
DK1092429T3 (en) 2004-07-19
NO306929B1 (en) 2000-01-17
CY2308B1 (en) 2003-11-14
HUT73661A (en) 1996-09-30
HU223073B1 (en) 2004-03-01
NO960062L (en) 1996-01-05
PL312255A1 (en) 1996-04-01
CN1496743A (en) 2004-05-19
ATE172876T1 (en) 1998-11-15
DK0710104T3 (en) 1999-07-19
NO306763B1 (en) 1999-12-20
FI960042A (en) 1996-01-04
CA2166204C (en) 2009-04-14
ES2124420T3 (en) 1999-02-01
EP0710103A1 (en) 1996-05-08
WO1995001785A1 (en) 1995-01-19
PT710103E (en) 2001-11-30
DE59410365D1 (en) 2004-04-22
ATE261720T1 (en) 2004-04-15
EP0710104A1 (en) 1996-05-08
AU7345794A (en) 1995-02-06
PT1092429E (en) 2004-08-31
NO960062D0 (en) 1996-01-05
PL179717B1 (en) 2000-10-31
DE59407239D1 (en) 1998-12-10
HU228127B1 (en) 2012-12-28
SK1996A3 (en) 1997-04-09
KR100359044B1 (en) 2003-02-05
JPH08512301A (en) 1996-12-24
NO960069L (en) 1996-01-05
CZ4596A3 (en) 1996-04-17
JPH08512303A (en) 1996-12-24
SI1092429T1 (en) 2004-08-31
CN1121853C (en) 2003-09-24
FI960032A0 (en) 1996-01-03
ES2218046T3 (en) 2004-11-16
CN1313154C (en) 2007-05-02
WO1995001786A1 (en) 1995-01-19
CN1128495A (en) 1996-08-07
HU9503965D0 (en) 1996-03-28
FI960032A (en) 1996-02-09
DE59409787D1 (en) 2001-07-19
DE4322826A1 (en) 1995-01-12
HU9503868D0 (en) 1996-02-28
KR100386533B1 (en) 2003-08-21
EP1092429A1 (en) 2001-04-18
JP2009138008A (en) 2009-06-25
FI960042A0 (en) 1996-01-04
NO960069D0 (en) 1996-01-05
AU7385094A (en) 1995-02-06
ATE201985T1 (en) 2001-06-15
EP1092429B1 (en) 2004-03-17
RU2140291C1 (en) 1999-10-27

Similar Documents

Publication Publication Date Title
NZ269552A (en) Pharmaceutical composition comprising sparingly water soluble agent in a carrier comprising a triglyceride, non-ionic surfactant and polyglycerol- or sorbitan fatty acid ester
BR9509496A (en) Pharmaceutical compositions
NZ512287A (en) Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
CA2390996A1 (en) Aqueous cleaning solutions containing elevated levels of n-alkyl-2-pyrrolidone
KR960033448A (en) Docosahexaenoic acid (DHA) -containing aqueous solution composition

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired